Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug

被引:0
|
作者
Sethuraman V.V. [1 ]
Hickey A.J. [2 ]
机构
[1] Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill
[2] School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill
关键词
Aerosol dispersion; Cohesive energy density; Dry powder inhalers; Surface area; Surface energy;
D O I
10.1208/pt030428
中图分类号
学科分类号
摘要
The purpose of this study was to determine if aerosol delivery of drug loaded microparticles to lungs infected with Mycobacterium tuberculosis may be achieved by predicting dispersion of dry powders through knowledge of particle surface properties. Particle sizes of rifampicin-loaded poly (lactide-co-glycolide) microparticles (R-PLGA), rifampicin alone, and lactose and maltodextrin carrier particles (bulk and 75-125-μ sieved fractions) were determined by electron microscopy for the projected area diameter (Dp) and laser diffraction for the volume diameter (Dv). Surface energies (y) of R-PLGA, rifampicin alone, lactose, and maltodextrin were obtained by inverse phase gas chromatography, surface areas (Sa) by N2 adsorption, and cohesive energy densities by calculation. Particle dispersion was evaluated (Andersen nonviable impactor) for 10% blends of R-PLGA and rifampicin alone with bulk and sieved fractions of the carriers. Dp for R-PLGA and rifampicin alone was 3.02 and 2.83 μm, respectively. Dv was 13 ± 1 and 2 ± 1 μm for R-PLGA and rifampicin alone, respectively, indicating that R-PLGA was more aggregated. This was evident in y of 35 ± 1 and 19 ± 6 mJ/m 2 for RPLGA and rifampicin alone. Dp for lactose and maltodextrin (sieved and bulk) was approximately 40 mm. Bulk maltodextrin (Dv = 119 ± 6 mm) was more aggregated than bulk lactose (Dv = 54 ± 2 mm). This was a result of the higher Sa for maltodextrin (0.54 m2/g) than for lactose (0.21 m2/g). The y of bulk lactose and maltodextrin was 40 ± 4 and 60 ± 6 mJ/m 2 and of sieved lactose and maltodextrin was 39 ± 1 and 50 ± 1 mJ/m2. Impaction studies yielded higher fine particle fractions of R-PLGA from sieved lactose, 13% ± 3%, than from sieved maltodextrin, 7% ± 1%, at 90 L/min. An expression, based on these data, is proposed as a predictor of drug dispersion from carrier particles. Delivery of dry powder formulations can be achieved by characterizing particle surfaces and predicting impact on dispersion.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system
    Everard, ML
    Devadason, SG
    LeSouef, PN
    THORAX, 1996, 51 (01) : 75 - 77
  • [22] A NEW DRY POWDER INHALER
    POVER, GM
    BROWNING, AK
    MULLINGER, BM
    BUTLER, AG
    DASH, CH
    PRACTITIONER, 1982, 226 (1365) : 565 - 567
  • [23] Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol
    Pavkov, Richard
    Mueller, Stefan
    Fiebich, Katrin
    Singh, Dilraj
    Stowasser, Frank
    Pignatelli, Giovanni
    Walter, Benoit
    Ziegler, Dominik
    Dalvi, Mukul
    Dederichs, Juergen
    Rietveld, Ilse
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (11) : 2527 - 2533
  • [24] The influence of carrier and drug morphology on drug delivery from dry powder formulations
    Larhrib, H
    Martin, GP
    Marriott, C
    Prime, D
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 257 (1-2) : 283 - 296
  • [25] Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery - A review for multidisciplinary researchers
    Islam, Nazrul
    Cleary, Matthew J.
    MEDICAL ENGINEERING & PHYSICS, 2012, 34 (04) : 409 - 427
  • [26] Freeze-Dried Mannitol for Superior Pulmonary Drug Delivery via Dry Powder Inhaler
    Kaialy, Waseem
    Nokhodchi, Ali
    PHARMACEUTICAL RESEARCH, 2013, 30 (02) : 458 - 477
  • [27] Numerical study of effects of device design on drug delivery efficiency for an active dry powder inhaler
    Dai, Wen
    Huang, Fen
    Yu, Jiaqi
    Li, Renjie
    Tong, Zhenbo
    JOURNAL OF AEROSOL SCIENCE, 2021, 157 (157)
  • [28] Importance of Powder Residence Time for the Aerosol Delivery Performance of a Commercial Dry Powder Inhaler Aerolizer®
    Jiang, Liqun
    Tang, Yue
    Zhang, Hongjiu
    Lu, Xifeng
    Chen, Xijing
    Zhu, Jiabi
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2012, 25 (05) : 265 - 279
  • [29] Freeze-Dried Mannitol for Superior Pulmonary Drug Delivery via Dry Powder Inhaler
    Waseem Kaialy
    Ali Nokhodchi
    Pharmaceutical Research, 2013, 30 : 458 - 477
  • [30] Improved Lung Delivery from a Passive Dry Powder Inhaler Using an Engineered PulmoSphere® Powder
    Sarma P. Duddu
    Steven A. Sisk
    Yulia H. Walter
    Thomas E. Tarara
    Kevin R. Trimble
    Andrew R. Clark
    Michael A. Eldon
    Rebecca C. Elton
    Matthew Pickford
    Peter H. Hirst
    Stephen P. Newman
    Jeffry G. Weers
    Pharmaceutical Research, 2002, 19 : 689 - 695